Pharming revenue falls 3% to $90.2 million

• Pharming reported second-quarter 2026 revenue of $90.2 million, down 3% year over year.
• RUCONEST sales declined 10% to $72.3 million, while Joenja revenue increased 40% to $17.9 million.
• The company reduced 2026 revenue guidance to $375–395 million as it prepares additional Joenja developments.

Pharming (NASDAQ:PHAR) reported preliminary second-quarter 2026 revenue of $90.2 million, down 3% year over year, as lower RUCONEST sales offset growth from Joenja.

The company’s gross profit declined 10% to $75.7 million, compared with the prior year, while revenue for the first half of 2026 fell 6% to $162.7 million.

Pharming reported operating profit of $1.3 million compared with $10.8 million in Q2 2025, while adjusted operating profit was $7.9 million and gross profit was affected by $4.9 million in manufacturing-related inventory impairments.

The company lowered its 2026 revenue guidance to $375–395 million, a $30 million reduction from previous expectations.

Pharming ended June 30, 2026, with $159.5 million in cash and marketable securities, while improving operating expense guidance to $315–320 million for the full year.

The company’s Joenja treatment received multiple approvals and launches, and Pharming said leniolisib clinical readouts in broader primary immunodeficiencies, including common variable immunodeficiency (CVID), are expected in Q4 2026.